TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial
The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
Background Activation of free fatty acid receptor 1 (FFAR1; also known as G-protein-coupled receptor 40) by fatty acids stimulated glucose-dependent β-cell insulin secretion in preclinical models. We aimed to assess whether selective pharmacological activation of this receptor by TAK-875 in patients with type 2 diabetes mellitus improved glycaemic control without hypoglycaemia risk.Methods We undertook a phase 2, randomised, double-blind, and placebo-controlled and active-comparator-controlled trial in outpatients with type 2 diabetes who had not responded to diet or metformin treatment. Patients were randomly assigned equally to receive placebo, TAK-875 (6·25, 25, 50, 100, or 200 mg), or glimepiride (4 mg) once daily for 12 weeks. Patients and investigators were masked to treatment assignment. The primary outcome was change in haemoglobin A(1c) (HbA(1c)) from baseline. Analysis included all patients randomly assigned to treatment groups who received at least one dose of double-blind study drug. The trial is registered at ClinicalTrials.gov, NCT01007097.Findings 426 patients were randomly assigned to TAK-875 (n=303), placebo (n=61), and glimepiride (n=62). At week 12, significant least-squares mean reductions in HbA(1c) from baseline occurred in all TAK-875 (ranging from -1·12% [SE 0·113] with 50 mg to -0·65% [0·114] with 6·25 mg) and glimepiride (-1·05% [SE 0·111]) groups versus placebo (-0·13% [SE 0·115]; p value range 0·001 to <0·0001). Treatment-emergent hypoglycaemic events were similar in the TAK-875 and placebo groups (2% [n=7, all TAK-875 groups] vs 3% [n=2]); significantly higher rates were reported in the glimepiride group (19% [n=12]; p value range 0·010-0·002 vs all TAK-875 groups). Incidence of treatment-emergent adverse events was similar in the TAK-875 overall (49%; n=147, all TAK-875 groups) and placebo groups (48%, n=29) and was lower than in the glimepiride group (61%, n=38).Interpretation TAK-875 significantly improved glycaemic control in patients with type 2 diabetes with minimum risk of hypoglycaemia. The results show that activation of FFAR1 is a viable therapeutic target for treatment of type 2 diabetes.Funding Takeda Global Research and Development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 1998, the landmark United Kingdom Prospective Diabetes Study (UKPDS) reported that improving glucose control primarily with sulphonylureas and insulin reduced microvascular complications in recently diagnosed patients with type 2 diabetes120.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [120]
In the citing paper
“The primary analysis did not show a clear benefit on macrovascular disease”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [120]
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040
Ogurtsova, K., da Rocha Fernandes, J. D., Huang, Y., Linnenkamp, U., Guariguata, L., Cho, N. H., Cavan, D., Shaw, J. E., & Makaroff, L. E. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.03.024 · Cited by 6,966
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030
Whiting, D. R., Guariguata, L., Weil, C., & Shaw, J. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.10.029 · Cited by 3,994
Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40
Itoh, Y., Kawamata, Y., Harada, M., Kobayashi, M., Fujii, R., Fukusumi, S., Ogi, K., Hosoya, M., Tanaka, Y., Uejima, H., et al. (2003) · Nature · doi:10.1038/nature01478 · Cited by 1,538
The Orphan G Protein-coupled Receptor GPR40 Is Activated by Medium and Long Chain Fatty Acids
Briscoe, C. P., Tadayyon, M., Andrews, J. L., Benson, W. G., Chambers, J. K., Eilert, M. M., Ellis, C., Elshourbagy, N. A., Goetz, A. S., Minnick, D. T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211495200 · Cited by 1,104
The G protein-coupled receptor repertoires of human and mouse
Vassilatis, D. K., Hohmann, J. G., Zeng, H., Li, F., Ranchalis, J. E., Mortrud, M. T., Brown, A., Rodriguez, S. S., Weller, J. R., Wright, A. C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230374100 · Cited by 790
Edfalk, S., Steneberg, P., & Edlund, H. (2008) · Diabetes · doi:10.2337/db08-0307 · Cited by 587
Management of type 2 diabetes: new and future developments in treatment
Tahrani, A. A., Bailey, C. J., Del Prato, S., & Barnett, A. H. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60207-9 · Cited by 533
Research works printed but not linked: 3
- Tsujihata, 2010, TAK-875, a novel, orally available GPR40 agonist, augments, glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats, Diabetes, 59, A165
- Takeuchi, 2010, A selective GPR40 agonist, TAK-875, stimulates glucose-dependent insulin secretion without beta cell toxicity and decreases glycosylated hemoglobin levels in diabetic rats, Diabetologia, 53, S353
- Leifke, 2011, Safety, tolerability, pharmacokinetics and pharmacodynamics of TAK-875, a novel GPR40 agonist, following once-daily oral administration for 2 weeks in type 2 diabetic patients [abstract 414-PP], Diabetes, 60, A114
Cited by
DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.19 · Cited by 2,611
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention
Wu, Y., Ding, Y., Tanaka, Y., & Zhang, W. (2014) · International Journal of Medical Sciences · doi:10.7150/ijms.10001 · Cited by 1,279
“A large number of chemical compounds which can act as GPR40 agonists exhibit glucose-dependent insulin secretion in vitro and in vivo, among which TAK-875 can reduce fasting plasma glucose and HbA1c levels in clinical trials [139].”
BackgroundFree Fatty Acid Receptors in Health and Disease
Kimura, I., Ichimura, A., Ohue-Kitano, R., & Igarashi, M. (2020) · Physiological Reviews · doi:10.1152/physrev.00041.2018 · Cited by 1,018
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
“The outcomes show that activation of FFAR1 is a viable therapeutic target for the treatment of T2DM [385] .”
Background
Metadata
- Authors
- Burant, C. F., Viswanathan, P., Marcinak, J., Cao, C., Vakilynejad, M., Xie, B., & Leifke, E.
- Affiliations
- University of Michigan (US)
- Takeda (United States) (US)
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2012-04
- Volume
- 379
- Issue
- 9824
- Pages
- 1403-1411
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2163448046
- Cited by
- 244
- References
- 26
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 9 · 2023: 2 · 2022: 8 · 2021: 14 · 2020: 13 · 2019: 13 · 2018: 18 · 2017: 14 · 2016: 28 · 2015: 19 · 2014: 37 · 2013: 36 · 2012: 24
- FWCI
- 30.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- TAK-875, free fatty acid receptor 1, GPR40, type 2 diabetes, glimepiride, glycemic control, HbA1c, hypoglycemia, insulin secretion, GLP-1 receptor agonists, adverse events
- MeSH terms
- Adult, Aged, Aged, 80 and over, Benzofurans, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Middle Aged, Sulfones, Sulfonylurea Compounds, Treatment Outcome, Risk Assessment, Maximum Tolerated Dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(11)61879-5
- The paper
- Burant, C. F., Viswanathan, P., Marcinak, J., Cao, C., Vakilynejad, M., Xie, B., & Leifke, E. (2012). TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(11)61879-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.